Steven J.KleinMD

Rheumatology • Hagerstown, MD

Rheumatoid Arthritis & Related

Physician

Join to view full profile

Dr. Klein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Klein's full profile

Already have an account?

Office
346 Mill St
Hagerstown, MD 21740
Phone+1 301-791-6680

Fax+1 301-714-1506

Education & Training

UPMC Medical Education (Harrisburg)Residency, Internal Medicine, 1987 - 1990
New York-Presbyterian Brooklyn Methodist HospitalInternship, Internal Medicine, 1986 - 1987
American University of the Caribbean School of MedicineClass of 1986

Certifications & Licensure

CA State Medical License 1991 - Present
MD State Medical License 1993 - 2026
FL State Medical License 1989 - 1998
PA State Medical License 1987 - 1996
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Fellow (FACR) American College of Rheumatology

Clinical Trials

An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2013 Jun 27
Completed
Phase 3
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis Start of enrollment: 2015 Sep 14
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 May 02
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 Apr 12
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis Start of enrollment: 2016 Aug 02
Completed
Phase 3
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease Start of enrollment: 2016 Jun 06
Completed
Phase 3
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Start of enrollment: 2017 May 09
Completed
Phase 3
Join now to see all

Professional Memberships

American College of Rheumatology - ACR
Fellow